SUPN - SUPERNUS PHARMACEUTICALS, INC.

QQQ $ 605.70 $ 0.00 (0 %)

DIA $ 464.85 $ 0.00 (0 %)

SPY $ 667.97 $ 0.00 (0 %)

TLT $ 91.53 $ 0.00 (0 %)

GLD $ 379.00 $ 0.00 (0 %)

Previous Close

$ 50.67

Open

$ 50.72

Bid

$ 49.51 x 100

Ask

$ 54.94 x 2

Day's Range

-- - --

52 Week Range

$ 29.16 - $ 52.15

Volume

561,904

Average Volume

Market Cap

2.84B

Beta (5Y Monthly)

$ 0.76

PE Ratio (TTM)

$ 44.05

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-05-2025	06-30-2025	10-Q
2	05-06-2025	03-31-2025	10-Q
3	02-25-2025	12-31-2024	10-K
4	11-04-2024	09-30-2024	10-Q
5	08-06-2024	06-30-2024	10-Q
6	05-08-2024	03-31-2024	10-Q
7	02-27-2024	12-31-2023	10-K
8	11-08-2023	09-30-2023	10-Q
9	08-08-2023	06-30-2023	10-Q
10	05-09-2023	03-31-2023	10-Q
11	03-09-2023	12-31-2022	10-K
12	11-09-2022	09-30-2022	10-Q
13	08-08-2022	06-30-2022	10-Q
14	05-12-2022	03-31-2022	10-Q
15	04-13-2022	12-31-2021	10-K
16	11-05-2021	09-30-2021	10-Q
17	08-06-2021	06-30-2021	10-Q
18	05-07-2021	03-31-2021	10-Q
19	03-08-2021	12-31-2020	10-K
20	11-06-2020	09-30-2020	10-Q
21	08-17-2020	06-30-2020	10-Q
22	05-15-2020	03-31-2020	10-Q
23	02-28-2020	12-31-2019	10-K
24	11-08-2019	09-30-2019	10-Q
25	08-09-2019	06-30-2019	10-Q
26	05-10-2019	03-31-2019	10-Q
27	03-01-2019	12-31-2018	10-K
28	11-09-2018	09-30-2018	10-Q
29	08-09-2018	06-30-2018	10-Q
30	05-10-2018	03-31-2018	10-Q
31	03-01-2018	12-31-2017	10-K
32	11-09-2017	09-30-2017	10-Q
33	08-03-2017	06-30-2017	10-Q
34	05-09-2017	03-31-2017	10-Q
35	03-16-2017	12-31-2016	10-K
36	01-20-2017	09-30-2016	10-Q
37	08-05-2016	06-30-2016	10-Q
38	05-10-2016	03-31-2016	10-Q
39	03-09-2016	12-31-2015	10-K
40	11-09-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

crowdstrike-to-rally-more-than-15-here-are-10-top-analyst-forecasts-for-thursday

Crowdstrike To Rally More Than 15%? Here A...
10/09/2025 12:20:44

Piper Sandler Upgrades Supernus Pharmaceut...
10/09/2025 11:54:54

Piper Sandler analyst David Amsellem upgrades Supernus Pharmaceuticals (NASDAQ:SUPN) from Neutral to Overweight and raises t...

Cantor Fitzgerald Maintains Overweight on ...
09/30/2025 14:13:28

Cantor Fitzgerald analyst Kristen Kluska maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and raises the p...

Piper Sandler Maintains Neutral on Supernu...
08/29/2025 13:18:21

Piper Sandler analyst David Amsellem maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Neutral and raises the price ta...

Cantor Fitzgerald Maintains Overweight on ...
08/06/2025 14:14:31

Cantor Fitzgerald analyst Kristen Kluska maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and raises the p...

Supernus Pharmaceuticals Raises FY2025 Sal...
08/05/2025 20:27:04

Supernus Pharmaceuticals (NASDAQ:SUPN) raises FY2025 sales outlook from $600.000 million-$630.000 million to $670.000 million-$...

Supernus Pharmaceuticals Q2 EPS $0.40 Beat...
08/05/2025 20:09:44

Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.40 per share which beat the analyst consensus estimate...

Earnings Scheduled For August 5, 2025
08/05/2025 08:32:54

Supernus Pharmaceuticals Clears Antitrust ...
07/28/2025 12:27:21

Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ:SUPN) ("Supernus", and the "Company"), today ann...

these-analysts-revise-their-forecasts-on-sage-therapeutics-following-acquisition-news

These Analysts Revise Their Forecasts On S...
06/17/2025 18:22:48

supernus-pharma-acquires-maker-of-postpartum-depression-drug-zurzuvae-in-795-million-deal

Supernus Pharma Acquires Maker Of Postpart...
06/16/2025 13:45:42

Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies b...

Supernus Pharmaceuticals Agrees To Buy Sag...
06/16/2025 11:02:32

Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.S...

Supernus Pharmaceuticals Affirms FY2025 Sa...
05/06/2025 20:21:37

Supernus Pharmaceuticals (NASDAQ:SUPN) affirms FY2025 sales outlook from $600.00 million-$630.00 million to $600.00 million-$63...

Supernus Pharmaceuticals Q1 2025 GAAP EPS ...
05/06/2025 20:20:22

Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly losses of $(0.21) per share. The company reported quarterly sales of...

Earnings Scheduled For May 6, 2025
05/06/2025 08:32:41

Uncovering Potential: Supernus Pharmaceuti...
05/05/2025 17:01:50

Cantor Fitzgerald Reiterates Neutral on Su...
02/26/2025 13:51:30

Cantor Fitzgerald analyst Kristen Kluska reiterates Supernus Pharmaceuticals (NASDAQ:SUPN) with a Neutral and maintains $36 ...

Supernus Pharmaceuticals Sees FY2025 Sales...
02/25/2025 21:08:53

Supernus Pharmaceuticals (NASDAQ:SUPN) sees FY2025 sales of $600.000 million-$630.000 million vs $622.18 million analyst estimate.

Supernus Pharmaceuticals Q4 EPS $0.27 Miss...
02/25/2025 21:08:13

Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.27 per share which missed the analyst consensus estima...

Earnings Scheduled For February 25, 2025
02/25/2025 08:32:24